medigraphic.com
ISSN 1561-3070 (Electronic)

2014, Number 2

<< Back Next >>

Rev Cub Oftal 2014; 27 (2)

Bioethical aspects of the treatment of diabetic retinopathy

Hernández PA, Tirado MOM

Language: Spanish
References: 29
Page: 272-282
PDF size: 119.09 Kb.


ABSTRACT

Medicine is such an old practice as the mankind. It has been modified and enriched with the scientific and technical revolution advances, but it always follows the same principles and ethical standards that set the physician-patient relationship based on respect, confidence and the Hippocratic precept of doing no harm. In the medical practice, most of the diagnostic, therapeutic and prophylactic procedures involve risks. This is especially true for the biomedical research and mainly for all those novel diagnostic and therapeutic methods which can cause some damage when applied. Diabetic retinopathy is one of the main causes of blindness in working-age patients. Searching alternative treatments for this illness should always evaluate the risks and the advantages


REFERENCES

  1. Sohl P, Bassford HA. Codes of Medical Ethics: Traditional Foundations and Contemporary Practice. Soc Sci Med. 1986;22(11):1175-9.

  2. Bilbeny N. Aproximación a la ética. Bogotá: Editorial Planeta; 1992. p. 15.

  3. Morales Gallego ML. Los nuevos avances científicos y la bioética. Madrid: Cultiva Comunicación SL; 2009.4. Sáenz T, Capote EG. Ciencia y tecnología en Cuba. Antecedentes y Desarrollo. La Habana: Ciencias Sociales; 1980.

  4. Sáenz T, Capote EG. Ciencia y tecnología en Cuba. Antecedentes y Desarrollo. La Habana: Ciencias Sociales; 1980.

  5. Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of diabetic retinopathy in the United States, 20052008. JAMA. 2010;304(6):649-56.

  6. Crespo N, Padilla JC, González R, Crespo N, Rodríguez M, Hernández JD. Prevalencia de la retinopatía diabética en pacientes del nivel primario de salud. Rev Cubana Med Gen Integr. 2004;20(2):111.

  7. Programa de Prevención de la Ceguera. Argentina; 2005 [citado: 29 de abril de 2014]. Disponible en: http://www.msal.gob.ar/ver/pdf/prog-nac-prev-ceguera.pdf

  8. Padrón ME, Sigler A, Mir RE, Esteban IC. Resultados del Programa de Salud Ocular en la provincia Ciego de Ávila. MediCiego. 2007 [citado: 12 de julio de 2013];13(1 Supl.):[aprox 7 p.]. Disponible en: http://bvs.sld.cu/revistas/mciego/vol13_supl1_07/articulos/a5_v13_supl107.html

  9. Hart W, Collazo M. Costos del diagnóstico y tratamiento de la diabetes mellitus en diferentes países del mundo. Rev Cub Endocrinol. 1998;9(3):212-20.

  10. Lansingh VC. Impacto de la ceguera en Latinoamérica-Costo. Vision 2020. [citado: 12 de julio de 2013]:[aprox. 12 p.]. Disponible en: http://www.paho.org/per/images/stories /FtPage/2013/Costo-Ceguera_espaol_Van-Lansingh.pdf

  11. Cruz LD. Costo de atención en el centro de especialidades médicas del estado de Veracruz “Dr. Rafael Lucio”, y en particular por retinopatía, asociada a Diabetes Mellitus tipo 2[tesis]. Centro de especialidades médicas del Estado de Veracruz (CEMEV); 2008.

  12. De Souza J, Mato A, Santamaría J, Cheaz J. La dimensión de “estrategia” en la construcción de la sostenibilidad institucional. San José, Costa Rica: Servicio Internacional para la Investigación Agrícola Nacional (ISNAR); 2001.

  13. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study (DRS) findings, DRS Report Number 8. Ophthalmology. 1981;88:583-600.

  14. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology. 1995;102(4):647-61.

  15. Machemer R, Parel JM, Norton EW. Vitrectomy: a pars plana approach. Technical improvements and further results. Trans Am Acad Ophthalmol Otolaryngol. 1972;76(2):462-6.

  16. Tremolada G, Del Turco C, Lattanzio R, Maestroni S, Maestroni A, Bandello F, et al. The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal Anti-VEGF treatment. Exp Diabetes Res. 2012 [citado: 23 de septiembre de 2013]:[aprox 2 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=Role+ of+Angiogenesis+in+the+Development+of+Proliferative+Diabetic+Retinopathy %3A+Impact+of+Intravitreal+Anti -VEGF+Treatmen

  17. Arévalo JF, Sánchez JG, Lasave AF, Wu L, Maia M, Bonafonte S, et al. Intravitreal Bevacizumab (Avastin) for diabetic retinopathy: The 2010 GLADAOF Lecture. 2013 [citado: 16 de noviembre de 2013]:[aprox 2p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=Intravitreal+Bevacizumab+%28Avast in%29+for+Diabetic+Retinopathy%3A+The+2010+GLADAOF+Lecture

  18. Erdol H, Turk A, Akyol N, Imamoglu HI. The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina. 2010;30(4):570-7.

  19. Arévalo JF, Wu L, Sánchez JG, Maia M, Saravia MJ, Fernández CF, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye. 2009;23(1):117-23.

  20. Schmidinger G, Maar N, Bolz M, Scholda C, Schmidt-Erfurth U. Repeated intravitreal bevacizumab (Avastin) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol. 2011;89(1):76-81.

  21. Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol. 2009;127(2):132-40.

  22. Cho WB, Moon JW, Kim HC. Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. Br J Ophthalmol. 2010;94(7):858-63.

  23. Alezzandrini AA. Bevacizumab intravítrea en retinopatía diabética proliferante. Buenos Aires: Arch Oftalmol. 2009;80(2):68-70.

  24. Demir M, Oba E, Can E, Kara O, Cinar S. Effect of Bevacizumab Injection before Vitrectomy on Intravitreal Hemorrhage in Pseudophakic Patients with Proliferative Diabetic Retinopathy. Ophthalmol Eye Dis. 2013;5:11-5.

  25. Li CR, Sun SG, Hong W. Effect of intravitreal bevacizumab injection before vitrectomy on proliferative diabetic retinopathy. Int J Ophthalmol. 2010;3(3):261-3.

  26. Arévalo JF, Maia M, Flynn HW, Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213-6.

  27. Ahn J, Woo SJ, Chung H, Park KH. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 2011;118(11):2218-26.

  28. Lolas F. Bioética en América Latina. Una década de evolución. Acta bioeth.2010;16(1):93.

  29. de Micheli A. En torno a la ética profesional del médico. Gac Méd Méx. 2004. [citado: 21 de: noviembre de 2013];140(1). Disponible en: http://www.medigraphic.com/pdfs/gaceta/gm-2004/gm041m.pdf




2020     |     www.medigraphic.com